- In March 2024, Synthekine Inc. an engineered cytokine therapeutics company announced releasing of Phase 1a/1b clinical trials of α/β biased IL-2 partial agonist, STK-012
- In March 2022, Xenco, a clinical-stage biopharmaceutical company announced developing engineered antibodies and cytokines to treat cancer and autoimmune diseases and are preclinical data presented from XmAb Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
